Park YH - Search Results

1

Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study.

Kang D, Yoon SE, Shin D, Lee J, Hong YS, Lee SK, Lee JE, Park YH, Ahn JS, Guallar E, Kim WS, Lee J, Kim SJ, Cho J. Kang D, et al. Among authors: park yh. Blood Cancer J. 2021 Dec 14;11(12):200. doi: 10.1038/s41408-021-00595-0. Blood Cancer J. 2021. PMID: 34907177 Free PMC article.

2

Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.

Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC, Park K. Lee J, et al. Among authors: park yh, park kw, park ys, park jo, park k. Eur J Cancer. 2005 Jul;41(10):1402-8. doi: 10.1016/j.ejca.2005.03.010. Eur J Cancer. 2005. PMID: 15963893

3

Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.

Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS. Lee J, et al. Among authors: park yh, park k, park j. J Clin Oncol. 2006 Feb 1;24(4):612-8. doi: 10.1200/JCO.2005.04.1384. Epub 2005 Dec 27. J Clin Oncol. 2006. PMID: 16380410

4

Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.

Park YH, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH. Park YH, et al. Among authors: park k. Ann Hematol. 2006 May;85(5):285-90. doi: 10.1007/s00277-005-0050-8. Epub 2006 Mar 4. Ann Hematol. 2006. PMID: 16518604

5

Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome.

Park YH, Kim WS, Bang SM, Lee SI, Kang HJ, Na II, Yang SH, Lee SS, Uhm JE, Kwon JM, Kim K, Jung CW, Park K, Ko YH, Ryoo BY. Park YH, et al. Among authors: park k. Leuk Res. 2006 Oct;30(10):1253-8. doi: 10.1016/j.leukres.2006.01.018. Epub 2006 Mar 9. Leuk Res. 2006. PMID: 16529813

6

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. Kim DH, et al. Among authors: park yh. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11. Blood. 2006. PMID: 16609067 Free article. Clinical Trial.

7

Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.

Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K. Oh SY, et al. Among authors: park yh, park kw, park k. Ann Hematol. 2006 Nov;85(11):781-6. doi: 10.1007/s00277-006-0160-y. Epub 2006 Jul 18. Ann Hematol. 2006. PMID: 16847665

8

CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation.

Park YH, Lee SH, Kim WS, Bang SM, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH, Lee J, Ko YH, Ahn YC, Lim DH, Park K. Park YH, et al. Among authors: park kw, park k. Leuk Lymphoma. 2006 Jul;47(7):1253-9. doi: 10.1080/10428190600556239. Leuk Lymphoma. 2006. PMID: 16923554 Clinical Trial.

9

What is stage II in high-grade primary gastric lymphoma? How to define the range of "localized disease".

Park YH, Kim WS, Bang SM, Lee SI, Uhm JE, Yang SH, Lee SS, Park K, Ko YH, Ryoo BY. Park YH, et al. Among authors: park k. Leuk Res. 2007 Aug;31(8):1039-43. doi: 10.1016/j.leukres.2006.08.021. Epub 2006 Oct 6. Leuk Res. 2007. PMID: 17027954

10

High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 cases in the Korean population.

Cho JH, Park YH, Kim WS, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS. Cho JH, et al. Among authors: park yh, park k. Leuk Lymphoma. 2006 Oct;47(10):2128-31. doi: 10.1080/10428190600783395. Leuk Lymphoma. 2006. PMID: 17071486

11

Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.

Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K. Oh SY, et al. Among authors: park yh, park k, park j. Am J Hematol. 2007 Jun;82(6):446-52. doi: 10.1002/ajh.20874. Am J Hematol. 2007. PMID: 17266060 Free article.

12

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.

Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS. Park S, et al. Among authors: park yh, park k. Blood. 2007 Aug 1;110(3):972-8. doi: 10.1182/blood-2007-01-067769. Epub 2007 Mar 30. Blood. 2007. PMID: 17400912 Free article. Clinical Trial.

13

Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type.

Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, Park K, Park YH, Ko YH, Kim WS. Lee J, et al. Among authors: park yh, park k. Clin Cancer Res. 2007 Jun 1;13(11):3250-4. doi: 10.1158/1078-0432.CCR-06-2373. Clin Cancer Res. 2007. PMID: 17545530

14

Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.

Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ. Oh SY, et al. Among authors: park yh. Eur J Haematol. 2007 Oct;79(4):287-91. doi: 10.1111/j.1600-0609.2007.00925.x. Epub 2007 Aug 10. Eur J Haematol. 2007. PMID: 17692101

15

Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.

Kang HJ, Kim WS, Suh C, Park YH, Kim BS, Yuh YJ, Ryoo BY. Kang HJ, et al. Among authors: park yh. Cancer Chemother Pharmacol. 2008 Jul;62(2):299-304. doi: 10.1007/s00280-007-0607-4. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922274 Clinical Trial.

16

Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.

Oh SY, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ. Oh SY, et al. Among authors: park yh, park k, park j. Cancer Lett. 2007 Dec 8;258(1):90-7. doi: 10.1016/j.canlet.2007.08.012. Cancer Lett. 2007. PMID: 17936499

17

Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group.

Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, Park S, Park BB, Ko YH, Kim K, Koo HH, Kim WS. Hwang IG, et al. Among authors: park bb, park yh, park s. Clin Lymphoma Myeloma. 2007 Nov;7(9):580-6. doi: 10.3816/clm.2007.n.044. Clin Lymphoma Myeloma. 2007. PMID: 18186966

18

High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.

Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, Cho JH, Lee M, Jung HH, Ki SS, Chang YH, Lee SS, Park YH, Lee KH. Park SC, et al. Among authors: park yh. J Med Virol. 2008 Jun;80(6):960-6. doi: 10.1002/jmv.21168. J Med Virol. 2008. PMID: 18428141

19

Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma.

Kim WS, Park YH, Lee SH, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im DH, Kang JH, Lee J, Ko YH, Ahn YC, Lim DH, Park K, Bang SM. Kim WS, et al. Among authors: park yh, park kw, park k. Med Oncol. 2008;25(4):447-50. doi: 10.1007/s12032-008-9065-z. Epub 2008 Apr 23. Med Oncol. 2008. PMID: 18431552

20

Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?

Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam DH, Lee JI, Park W, Huh SJ, Park YH, Ahn JS, Im YH. Park BB, et al. Among authors: park yh, park w. Cancer Chemother Pharmacol. 2009 Mar;63(4):627-33. doi: 10.1007/s00280-008-0779-6. Epub 2008 Jun 14. Cancer Chemother Pharmacol. 2009. PMID: 18553084

21

Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells.

Park YH, Jung HH, Ahn JS, Im YH. Park YH, et al. Biochem Biophys Res Commun. 2008 Dec 12;377(2):389-394. doi: 10.1016/j.bbrc.2008.09.135. Epub 2008 Oct 11. Biochem Biophys Res Commun. 2008. PMID: 18851945

22

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ. Hong JY, et al. Among authors: park yh, park mj, park k. Med Oncol. 2009;26(3):287-91. doi: 10.1007/s12032-008-9117-4. Epub 2008 Nov 7. Med Oncol. 2009. PMID: 18989796

23

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Uhm JE, et al. Among authors: park yh, park mj, park k. Int J Cancer. 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090. Int J Cancer. 2009. PMID: 19065658 Free article.

24

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.

Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Chang MH, et al. Among authors: park yh, park mj, park k. Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: 10.1007/s00280-009-0943-7. Epub 2009 Feb 17. Cancer Chemother Pharmacol. 2009. PMID: 19221753 Clinical Trial.

25

Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.

Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ. Kim HS, et al. Among authors: park yh, park k. Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25. Oncology. 2009. PMID: 19246948

26

Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.

Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM, Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee NS, Gong SJ, Park K. Lee HY, et al. Among authors: park yh, park k. Lung Cancer. 2009 Dec;66(3):338-43. doi: 10.1016/j.lungcan.2009.02.008. Epub 2009 Mar 18. Lung Cancer. 2009. PMID: 19299031 Clinical Trial.

27

Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer.

Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH. Kim HS, et al. Among authors: park yh, park mj, park k. Breast Cancer Res Treat. 2009 Nov;118(1):89-97. doi: 10.1007/s10549-009-0377-2. Epub 2009 Mar 26. Breast Cancer Res Treat. 2009. PMID: 19322651

28

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ. Park S, et al. Among authors: park yh, park k. J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4. J Thorac Oncol. 2009. PMID: 19487967 Free article.

29

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?

Kim KH, Lee J, Lee JI, Nam DH, Kong DS, Ahn YC, Park HC, Kwon OJ, Kim H, Chang MH, Yi SY, Ji SH, Park YH, Ahn JS, Park K, Ahn MJ. Kim KH, et al. Among authors: park yh, park hc, park k. Lung Cancer. 2010 May;68(2):258-63. doi: 10.1016/j.lungcan.2009.06.008. Epub 2009 Jul 9. Lung Cancer. 2010. PMID: 19592127

30

The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.

Choi JH, Lim HI, Lee SK, Kim WW, Kim SM, Cho E, Ko EY, Han BK, Park YH, Ahn JS, Im YH, Lee JE, Yang JH, Nam SJ. Choi JH, et al. Among authors: park yh. J Surg Oncol. 2010 Oct 1;102(5):392-7. doi: 10.1002/jso.21424. J Surg Oncol. 2010. PMID: 19877158

31

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.

Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Park YH, et al. Cancer Chemother Pharmacol. 2010 Aug;66(3):507-16. doi: 10.1007/s00280-009-1190-7. Epub 2009 Dec 3. Cancer Chemother Pharmacol. 2010. PMID: 19956951

32

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, Lee JE, Nam SJ, Yang JH, Park W, Choi DH, Huh SJ, Ahn JS, Im YH. Park YH, et al. Among authors: park w. Breast Cancer Res Treat. 2010 Feb;119(3):653-61. doi: 10.1007/s10549-009-0665-x. Breast Cancer Res Treat. 2010. PMID: 19957028

33

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K. Sun JM, et al. Among authors: park yh, park mj, park k. Lung Cancer. 2010 Jul;69(1):105-9. doi: 10.1016/j.lungcan.2009.09.014. Epub 2009 Dec 2. Lung Cancer. 2010. PMID: 19959251

34

Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy.

Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ. Sun JM, et al. Among authors: park yh, park k. Lung Cancer. 2010 Sep;69(3):330-6. doi: 10.1016/j.lungcan.2009.11.015. Epub 2009 Dec 14. Lung Cancer. 2010. PMID: 20007002

35

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.

Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K. Chang MH, et al. Among authors: park yh, park k. Lung Cancer. 2010 Sep;69(3):323-9. doi: 10.1016/j.lungcan.2009.12.002. Epub 2010 Jan 12. Lung Cancer. 2010. PMID: 20061047

36

Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer.

Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K, Ahn MJ. Chang MH, et al. Among authors: park yh, park k. APMIS. 2009 Dec;117(12):861-9. doi: 10.1111/j.1600-0463.2009.02545.x. APMIS. 2009. PMID: 20078550

37

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.

Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Sun JM, et al. Among authors: park yh, park jo, park k. J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d. J Thorac Oncol. 2010. PMID: 20195170 Free article.

38

Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor.

Jung HH, Park YH, Jun HJ, Kong J, Kim JH, Kim JA, Yun J, Sun JM, Won YW, Lee S, Kim ST, Ahn JS, Im YH. Jung HH, et al. Among authors: park yh. Mol Cancer Res. 2010 Jul;8(7):1037-47. doi: 10.1158/1541-7786.MCR-09-0469. Epub 2010 Jun 15. Mol Cancer Res. 2010. PMID: 20551150

39

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.

Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ. Sun JM, et al. Among authors: park yh, park k. J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16. J Cancer Res Clin Oncol. 2011. PMID: 20552223

40

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: park yh, park k. Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130. Cancer. 2010. PMID: 20564408 Free article.

41

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.

Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K. Sun JM, et al. Among authors: park yh, park hc, park k. Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3. Lung Cancer. 2011. PMID: 20598769

42

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ. Chang MH, et al. Among authors: park yh, park k. Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560. Epub 2010 Aug 27. Cancer. 2011. PMID: 20803614 Free article.

43

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH. Yi SY, et al. Among authors: park yh, park mj. BMC Cancer. 2010 Oct 5;10:527. doi: 10.1186/1471-2407-10-527. BMC Cancer. 2010. PMID: 20920367 Free PMC article.

44

Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.

Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: park yh, park k. Oncology. 2010;79(1-2):78-84. doi: 10.1159/000320190. Epub 2010 Nov 12. Oncology. 2010. PMID: 21071994

45

Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).

Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Cho EY, et al. Among authors: park yh. Cancer Chemother Pharmacol. 2011 Sep;68(3):753-61. doi: 10.1007/s00280-010-1548-x. Epub 2010 Dec 18. Cancer Chemother Pharmacol. 2011. PMID: 21170648

46

Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH. Lee SJ, et al. Among authors: park yh. Cancer Chemother Pharmacol. 2011 Sep;68(3):743-51. doi: 10.1007/s00280-010-1545-0. Epub 2010 Dec 18. Cancer Chemother Pharmacol. 2011. PMID: 21170649

47

ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.

Park S, Jung HH, Park YH, Ahn JS, Im YH. Park S, et al. Among authors: park yh. Biochem Biophys Res Commun. 2011 Apr 22;407(4):680-6. doi: 10.1016/j.bbrc.2011.03.075. Epub 2011 Apr 2. Biochem Biophys Res Commun. 2011. PMID: 21440529

48

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.

Lee S, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ. Lee S, et al. Among authors: park yh, park k. J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11. doi: 10.1007/s00432-011-0986-0. Epub 2011 May 28. J Cancer Res Clin Oncol. 2011. PMID: 21626008 Free PMC article.

49

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: park yh, park k. Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022. Lung Cancer. 2012. PMID: 21684626 Clinical Trial.

50

Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.

Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH. Lee S, et al. Among authors: park yh, park kt, park w. Breast Cancer Res Treat. 2011 Oct;129(3):809-17. doi: 10.1007/s10549-011-1682-0. Epub 2011 Jul 23. Breast Cancer Res Treat. 2011. PMID: 21785952 Clinical Trial.

51

Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer.

Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Lee SJ, et al. Among authors: park yh, park s. Cancer Res Treat. 2011 Jun;43(2):89-95. doi: 10.4143/crt.2011.43.2.89. Epub 2011 Jun 30. Cancer Res Treat. 2011. PMID: 21811424 Free PMC article.

52

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.

Ahn MJ, Won HH, Lee J, Lee ST, Sun JM, Park YH, Ahn JS, Kwon OJ, Kim H, Shim YM, Kim J, Kim K, Kim YH, Park JY, Kim JW, Park K. Ahn MJ, et al. Among authors: park yh, park jy, park k. Hum Genet. 2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25. Hum Genet. 2012. PMID: 21866343

53

Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations.

Kong JH, Park YH, Kim JA, Kim JH, Yun J, Sun JM, Won YW, Lee S, Kim ST, Cho EY, Ahn JS, Im YH. Kong JH, et al. Among authors: park yh. Oncology. 2011;81(1):55-62. doi: 10.1159/000331417. Epub 2011 Sep 16. Oncology. 2011. PMID: 21934337

54

Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: is there a subpopulation that might have benefit from adjuvant chemotherapy?

Park YH, Im SA, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Park YH, et al. Breast Cancer Res Treat. 2012 May;133(1):247-55. doi: 10.1007/s10549-012-1956-1. Epub 2012 Jan 21. Breast Cancer Res Treat. 2012. PMID: 22270935

55

Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.

Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Lee JY, Park KT, Ahn JS, Park YH, Im YH. Park S, et al. Among authors: park yh, park kt, park lc. Oncology. 2012;82(3):180-7. doi: 10.1159/000336081. Epub 2012 Mar 16. Oncology. 2012. PMID: 22433564

56

Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram.

Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH. Ahn HK, et al. Among authors: park yh, park s, park w. Neuro Oncol. 2012 Aug;14(8):1105-13. doi: 10.1093/neuonc/nos137. Epub 2012 Jun 11. Neuro Oncol. 2012. PMID: 22693244 Free PMC article.

57

Prognostic impact of FOXP3 expression in triple-negative breast cancer.

Lee S, Cho EY, Park YH, Ahn JS, Im YH. Lee S, et al. Among authors: park yh. Acta Oncol. 2013 Jan;52(1):73-81. doi: 10.3109/0284186X.2012.731520. Epub 2012 Oct 17. Acta Oncol. 2013. PMID: 23075422

58

Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.

Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, Nam SJ, Lee JE, Lee SK, Im YH, Park YH. Ko ES, et al. Among authors: park yh. Ann Surg Oncol. 2013 Aug;20(8):2562-8. doi: 10.1245/s10434-013-2925-6. Epub 2013 Mar 6. Ann Surg Oncol. 2013. PMID: 23463090

59

Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.

Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH. Park YH, et al. Among authors: park ih, park hs. J Clin Oncol. 2013 May 10;31(14):1732-9. doi: 10.1200/JCO.2012.45.2490. Epub 2013 Apr 8. J Clin Oncol. 2013. PMID: 23569309 Clinical Trial.

60

Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes.

Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, Choi DH, Hur SJ, Ahn JS, Im YH. Ahn HK, et al. Among authors: park yh, park s, park w. Springerplus. 2013 Mar 28;2(1):136. doi: 10.1186/2193-1801-2-136. Print 2013 Dec. Springerplus. 2013. PMID: 23667803 Free PMC article.

61

Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.

Park YH, Jung HH, Ahn JS, Im YH. Park YH, et al. Biochem Biophys Res Commun. 2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21. Biochem Biophys Res Commun. 2013. PMID: 23973711

62

Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.

Lee SY, Im SA, Park YH, Woo SY, Kim S, Choi MK, Chang W, Ahn JS, Im YH. Lee SY, et al. Among authors: park yh. Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18. Eur J Cancer. 2014. PMID: 24361227 Clinical Trial.

63

Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients.

Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH, Cho J. Choi EK, et al. Among authors: park yh. Psychooncology. 2014 Oct;23(10):1103-10. doi: 10.1002/pon.3531. Epub 2014 Mar 24. Psychooncology. 2014. PMID: 24664939

64

Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma.

Park LC, Jeong JY, Ji JH, Park S, Ahn JS, Im YH, Park YH. Park LC, et al. Among authors: park yh, park s. Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22. Cancer Res Treat. 2014. PMID: 24851113 Free PMC article.

65

Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.

Park YH, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH. Park YH, et al. Among authors: park ia. Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4. Oncology. 2014. PMID: 24903080

66

Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.

Choi MK, Park YH, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Choi MK, et al. Among authors: park yh. Cancer Chemother Pharmacol. 2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22. Cancer Chemother Pharmacol. 2014. PMID: 25047725

67

Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.

Jung HA, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Jung HA, et al. Among authors: park yh. Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19. Tumour Biol. 2015. PMID: 25326808

68

Association between socioeconomic status and altered appearance distress, body image, and quality of life among breast cancer patients.

Chang O, Choi EK, Kim IR, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Cho J. Chang O, et al. Among authors: park yh. Asian Pac J Cancer Prev. 2014;15(20):8607-12. doi: 10.7314/apjcp.2014.15.20.8607. Asian Pac J Cancer Prev. 2014. PMID: 25374176 Free article.

69

Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.

Hyun SH, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY. Hyun SH, et al. Among authors: park yh. Radiology. 2015 Apr;275(1):235-44. doi: 10.1148/radiol.14141129. Epub 2014 Dec 11. Radiology. 2015. PMID: 25496075

70

A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.

Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH. Park YH, et al. Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24. Int J Cancer. 2015. PMID: 25537444 Free article.

71

Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer.

Lee JY, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sohn I, Gil WH, Lee JE, Kim SW, Nam SJ, Ahn JS, Im YH, Park YH. Lee JY, et al. Among authors: park yh. Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13. Cancer Res Treat. 2015. PMID: 25622590 Free PMC article.

72

The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.

Kim J, Han W, Jung SY, Park YH, Moon HG, Ahn SK, Lee JW, Kim MK, Kim JJ, Lee ES, You TK, Kang HS, Lee ES, Ro J, Lee JE, Nam SJ, Yim YH, Park IA, Noh DY. Kim J, et al. Among authors: park yh, park ia. Ann Surg Oncol. 2015 Oct;22(11):3481-8. doi: 10.1245/s10434-015-4399-1. Epub 2015 Feb 5. Ann Surg Oncol. 2015. PMID: 25652052

73

Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea.

Park YH, Lee SJ, Jung HA, Kim SM, Kim MJ, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Park YH, et al. Breast. 2015 Jun;24(3):213-7. doi: 10.1016/j.breast.2015.01.012. Epub 2015 Feb 24. Breast. 2015. PMID: 25728283

74

Proportion and clinical outcomes of postoperative radiotherapy omission after breast-conserving surgery in women with breast cancer.

Yu JI, Choi DH, Huh SJ, Park W, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH. Yu JI, et al. Among authors: park yh, park w. J Breast Cancer. 2015 Mar;18(1):50-6. doi: 10.4048/jbc.2015.18.1.50. Epub 2015 Mar 27. J Breast Cancer. 2015. PMID: 25834611 Free PMC article.

75

Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management.

Yu JI, Park W, Choi DH, Huh SJ, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH, Cho EY. Yu JI, et al. Among authors: park yh, park w. Clin Breast Cancer. 2015 Aug;15(4):e197-204. doi: 10.1016/j.clbc.2015.03.006. Epub 2015 Mar 24. Clin Breast Cancer. 2015. PMID: 25957739

76

Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.

Hong JY, Park YH, Choi MK, Jung HA, Lee SJ, Ahn JS, Im YH. Hong JY, et al. Among authors: park yh. Clin Breast Cancer. 2015 Oct;15(5):e287-92. doi: 10.1016/j.clbc.2015.04.004. Epub 2015 Apr 23. Clin Breast Cancer. 2015. PMID: 25997855

77

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.

Park K, Choi MK, Jung HH, Do IG, Lee KH, Ahn T, Kil WH, Kim SW, Lee JE, Nam SJ, Kim DH, Ahn JS, Im YH, Park YH. Park K, et al. Among authors: park yh. Oncotarget. 2015 Sep 15;6(27):24499-510. doi: 10.18632/oncotarget.4119. Oncotarget. 2015. PMID: 26009992 Free PMC article.

78

Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).

Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS; Korean Cancer Study Group (KCSG); Im YH. Park YH, et al. Among authors: park ih, park hs. Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2. Breast Cancer Res Treat. 2015. PMID: 26033708 Clinical Trial.

79

Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments.

Yu JI, Park W, Choi DH, Huh SJ, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH, Cho EY. Yu JI, et al. Among authors: park yh, park w. Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18. Clin Breast Cancer. 2015. PMID: 26188791

80

Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study.

Kang D, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J. Kang D, et al. Among authors: park yh, park h. Breast Cancer Res Treat. 2015 Aug;152(3):675-82. doi: 10.1007/s10549-015-3502-4. Epub 2015 Jul 22. Breast Cancer Res Treat. 2015. PMID: 26198993

81

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.

Park YH, Shin HT, Jung HH, Choi YL, Ahn T, Park K, Lee A, Do IG, Kim JY, Ahn JS, Park WY, Im YH. Park YH, et al. Among authors: park k, park wy. Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184. Oncotarget. 2015. PMID: 26397225 Free PMC article.

82

Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.

Lee JY, Park K, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Hong M, Do IG, Ahn T, Lee SK, Bae SY, Kim SW, Lee JE, Nam SJ, Kim DH, Jung HH, Kim JY, Ahn JS, Im YH, Park YH. Lee JY, et al. Among authors: park yh, park k. Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192. Oncotarget. 2015. PMID: 26527317 Free PMC article.

83

Limited Supraclavicular Radiation Field in Breast Cancer With ≥ 10 Positive Axillary Lymph Nodes.

Yu JI, Park W, Choi DH, Huh SJ, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH, Cho EY. Yu JI, et al. Among authors: park yh, park w. Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11. Clin Breast Cancer. 2016. PMID: 26732519

84

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC).

Lee JY, Lim SH, Lee MY, Kim HS, Ahn JS, Im YH, Park YH. Lee JY, et al. Among authors: park yh. PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016. PLoS One. 2016. PMID: 26901062 Free PMC article. Clinical Trial.

85

Prognostic value of ERBB4 expression in patients with triple negative breast cancer.

Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im YH. Kim JY, et al. Among authors: park yh. BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3. BMC Cancer. 2016. PMID: 26907936 Free PMC article.

86

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer.

Kim JY, Park K, Jung HH, Lee E, Cho EY, Lee KH, Bae SY, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH. Kim JY, et al. Among authors: park yh, park k. Cancer Res Treat. 2016 Oct;48(4):1338-1350. doi: 10.4143/crt.2015.430. Epub 2016 Feb 18. Cancer Res Treat. 2016. PMID: 26910472 Free PMC article.

87

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea.

Kim HK, Ham JS, Byeon S, Yoo KH, Jung KS, Song HN, Cho J, Lee JY, Lim SH, Kim HS, Kim JY, Lee JE, Kim SW, Nam SJ, Lee SK, Bae SY, Ahn JS, Im YH, Park YH. Kim HK, et al. Among authors: park yh. Cancer Res Treat. 2016 Oct;48(4):1382-1388. doi: 10.4143/crt.2015.423. Epub 2016 Mar 11. Cancer Res Treat. 2016. PMID: 26987392 Free PMC article.

88

Gene Expression Profiling of Breast Cancer Brain Metastasis.

Lee JY, Park K, Lee E, Ahn T, Jung HH, Lim SH, Hong M, Do IG, Cho EY, Kim DH, Kim JY, Ahn JS, Im YH, Park YH. Lee JY, et al. Among authors: park yh, park k. Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623. Sci Rep. 2016. PMID: 27340107 Free PMC article.

89

Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes.

Kim SW, Choi DH, Huh SJ, Park W, Nam SJ, Kim SW, Lee JE, Im YH, Ahn JS, Park YH. Kim SW, et al. Among authors: park yh, park w. J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24. J Breast Cancer. 2016. PMID: 27382393 Free PMC article.

90

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.

Kim JY, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH. Kim JY, et al. Among authors: park yh. Sci Rep. 2016 Aug 22;6:31804. doi: 10.1038/srep31804. Sci Rep. 2016. PMID: 27545642 Free PMC article.

91

Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.

Jung HH, Lee SH, Kim JY, Ahn JS, Park YH, Im YH. Jung HH, et al. Among authors: park yh. Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035. Sci Rep. 2016. PMID: 27604655 Free PMC article.

92

Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series.

Lee MY, Chang WJ, Kim HS, Lee JY, Lim SH, Lee JE, Kim SW, Nam SJ, Ahn JS, Im YH, Park YH. Lee MY, et al. Among authors: park yh. PLoS One. 2016 Sep 20;11(9):e0163254. doi: 10.1371/journal.pone.0163254. eCollection 2016. PLoS One. 2016. PMID: 27648567 Free PMC article.

93

Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.

Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY. Choi M, et al. Among authors: park yh. Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11. Breast Cancer Res Treat. 2016. PMID: 27730423

94

Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer.

Hyun SH, Ahn HK, Lee JH, Choi JY, Kim BT, Park YH, Im YH, Lee JE, Nam SJ, Lee KH. Hyun SH, et al. Among authors: park yh. PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016. PLoS One. 2016. PMID: 27798667 Free PMC article.

95

Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy.

Kim H, Park W, Huh SJ, Choi DH, Noh JM, Im YH, Ahn JS, Park YH, Nam SJ, Kim SW, Lee JE, Cho EY. Kim H, et al. Among authors: park yh, park w. Asia Pac J Clin Oncol. 2017 Aug;13(4):329-336. doi: 10.1111/ajco.12652. Epub 2016 Nov 21. Asia Pac J Clin Oncol. 2017. PMID: 27869361

96

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.

Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY. Choi M, et al. Among authors: park yh. J Pathol Transl Med. 2017 Jan;51(1):69-78. doi: 10.4132/jptm.2016.10.05. Epub 2016 Dec 25. J Pathol Transl Med. 2017. PMID: 28013533 Free PMC article.

97

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.

Kim JY, Park K, Lee E, Jung HH, Ahn JS, Im YH, Park WY, Park YH. Kim JY, et al. Among authors: park yh, park k, park wy. Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414. Oncotarget. 2017. PMID: 28060723 Free PMC article.

98

Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls.

Kang D, Choi EK, Kim IR, Nam SJ, Lee JE, Im YH, Ahn JS, Park YH, Cho J. Kang D, et al. Among authors: park yh. Palliat Support Care. 2018 Apr;16(2):137-145. doi: 10.1017/S1478951517000062. Epub 2017 Mar 6. Palliat Support Care. 2018. PMID: 28262081

99

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.

Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH. Kim JY, et al. Among authors: park yh, park k, park wy. Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881. Oncotarget. 2017. PMID: 28427202 Free PMC article.

100

Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.

Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, Ryu HS, Kim S, Lee JE, Park YH, Kan Z, Han W, Park WY. Chung W, et al. Among authors: park yh, park wy. Nat Commun. 2017 May 5;8:15081. doi: 10.1038/ncomms15081. Nat Commun. 2017. PMID: 28474673 Free PMC article.

101

A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.

Kim JY, Ok ON, Seo JJ, Lee SH, Ahn JS, Im YH, Park YH. Kim JY, et al. Among authors: park yh. Breast Cancer Res Treat. 2017 Aug;164(3):617-625. doi: 10.1007/s10549-017-4268-7. Epub 2017 May 9. Breast Cancer Res Treat. 2017. PMID: 28488142 Clinical Trial.

102

Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.

Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH. Kim JY, et al. Among authors: park yh, park k, park wy. Oncotarget. 2017 Jul 18;8(29):47400-47411. doi: 10.18632/oncotarget.17653. Oncotarget. 2017. PMID: 28537889 Free PMC article.

103

Prevalence and detection of low-allele-fraction variants in clinical cancer samples.

Shin HT, Choi YL, Yun JW, Kim NKD, Kim SY, Jeon HJ, Nam JY, Lee C, Ryu D, Kim SC, Park K, Lee E, Bae JS, Son DS, Joung JG, Lee J, Kim ST, Ahn MJ, Lee SH, Ahn JS, Lee WY, Oh BY, Park YH, Lee JE, Lee KH, Kim HC, Kim KM, Im YH, Park K, Park PJ, Park WY. Shin HT, et al. Among authors: park yh, park pj, park k, park wy. Nat Commun. 2017 Nov 9;8(1):1377. doi: 10.1038/s41467-017-01470-y. Nat Commun. 2017. PMID: 29123093 Free PMC article.

104

Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast.

Kim JY, Yu JH, Nam SJ, Kim SW, Lee SK, Park WY, Noh DY, Nam DH, Park YH, Han W, Lee JE. Kim JY, et al. Among authors: park yh, park wy. Transl Oncol. 2018 Feb;11(1):18-23. doi: 10.1016/j.tranon.2017.10.002. Epub 2017 Nov 13. Transl Oncol. 2018. PMID: 29145046 Free PMC article.

105

Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy.

Kim JY, Park D, Son DS, Nam SJ, Kim SW, Jung HH, Kim YJ, Park G, Park WY, Lee JE, Park YH. Kim JY, et al. Among authors: park yh, park d, park g, park wy. Oncotarget. 2017 Sep 23;8(49):86423-86434. doi: 10.18632/oncotarget.21198. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156805 Free PMC article.

106

Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy.

Park JH, Lee SK, Lee JE, Kim SW, Nam SJ, Kim JY, Ahn JS, Park W, Yu J, Park YH. Park JH, et al. Among authors: park yh, park w. J Breast Cancer. 2018 Mar;21(1):91-95. doi: 10.4048/jbc.2018.21.1.91. Epub 2018 Mar 23. J Breast Cancer. 2018. PMID: 29628989 Free PMC article.

107

Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.

Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, Cho S, Fernandez-Banet J, Lee SK, Kim SW, Lee JE, Choi YL, Deng S, Kim JY, Ahn JS, Sha Y, Mu XJ, Nam JY, Im YH, Lee S, Park WY, Nam SJ, Park YH. Kan Z, et al. Among authors: park yh, park wy. Nat Commun. 2018 Apr 30;9(1):1725. doi: 10.1038/s41467-018-04129-4. Nat Commun. 2018. PMID: 29713003 Free PMC article.

108

Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment.

Cho WK, Choi DH, Park W, Cha H, Nam SJ, Kim SW, Lee JE, Yu J, Im YH, Ahn JS, Park YH, Kim JY, Ahn S. Cho WK, et al. Among authors: park yh, park w. Clin Breast Cancer. 2018 Oct;18(5):e1141-e1147. doi: 10.1016/j.clbc.2018.04.010. Epub 2018 Apr 19. Clin Breast Cancer. 2018. PMID: 29753627

109

Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.

Kim JY, Lim JE, Jung HH, Cho SY, Cho EY, Lee SK, Yu JH, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Im YH. Kim JY, et al. Among authors: park yh. Breast Cancer Res Treat. 2018 Oct;171(3):737-745. doi: 10.1007/s10549-018-4858-z. Epub 2018 Jun 21. Breast Cancer Res Treat. 2018. PMID: 29931426

110

Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.

Lee DY, Park YH, Lee JE, Choi D. Lee DY, et al. Among authors: park yh. Breast Cancer Res Treat. 2018 Oct;171(3):649-656. doi: 10.1007/s10549-018-4863-2. Epub 2018 Jun 25. Breast Cancer Res Treat. 2018. PMID: 29943121

111

Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?

Cho WK, Park W, Choi DH, Cha H, Nam SJ, Kim SW, Lee JE, Yu J, Im YH, Ahn JS, Park YH, Kim JY. Cho WK, et al. Among authors: park yh, park w. J Breast Cancer. 2018 Jun;21(2):206-212. doi: 10.4048/jbc.2018.21.2.206. Epub 2018 Jun 20. J Breast Cancer. 2018. PMID: 29963117 Free PMC article.

112

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.

Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J. Kang D, et al. Among authors: park yh, park jh. Oncologist. 2019 Mar;24(3):414-420. doi: 10.1634/theoncologist.2018-0184. Epub 2018 Aug 17. Oncologist. 2019. PMID: 30120165 Free PMC article.

113

Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.

Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, Lee SC, Ahn JS, Park SW, Im YH, Jeon ES, Park YH. Kim EK, et al. Among authors: park yh, park sj, park sw. Cancer Res Treat. 2019 Apr;51(2):727-736. doi: 10.4143/crt.2018.262. Epub 2018 Sep 4. Cancer Res Treat. 2019. PMID: 30177584 Free PMC article.

114

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.

Kim HK, Park KH, Kim Y, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Lee JE, Ahn JS, Im YH, Yu JH, Park YH. Kim HK, et al. Among authors: park yh, park kh, park se. Cancer Res Treat. 2019 Apr;51(2):737-747. doi: 10.4143/crt.2018.342. Epub 2018 Sep 5. Cancer Res Treat. 2019. PMID: 30189722 Free PMC article.

115

Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer.

Park SE, Park K, Lee E, Kim JY, Ahn JS, Im YH, Lee C, Jung H, Cho SY, Park WY, Cristescu R, Park YH. Park SE, et al. Among authors: park yh, park k, park wy. Oncoimmunology. 2018 May 24;7(8):e1466768. doi: 10.1080/2162402X.2018.1466768. eCollection 2018. Oncoimmunology. 2018. PMID: 30221068 Free PMC article.

116

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).

Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH, Park YH, Kim TY, Kim SB, Lee KS, Kim GM, Kim SH, Kim S, Ahn JS, Lee KH, Ahn JH, Park IH, Im YH; breast cancer committee of Korean Cancer Study Group (KCSG). Kim JY, et al. Among authors: park yh, park ih. Eur J Cancer. 2018 Nov;103:127-136. doi: 10.1016/j.ejca.2018.08.004. Epub 2018 Sep 14. Eur J Cancer. 2018. PMID: 30223226 Clinical Trial.

117

A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.

Hwang HW, Jung H, Hyeon J, Park YH, Ahn JS, Im YH, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Choi M, Cho SY, Cho EY. Hwang HW, et al. Among authors: park yh. Breast Cancer Res Treat. 2019 Jan;173(2):255-266. doi: 10.1007/s10549-018-4981-x. Epub 2018 Oct 15. Breast Cancer Res Treat. 2019. PMID: 30324273 Review.

118

Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.

Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group. Ryu JM, et al. Among authors: park yh, park jh. Breast Cancer Res Treat. 2019 Jan;173(2):385-395. doi: 10.1007/s10549-018-5015-4. Epub 2018 Oct 22. Breast Cancer Res Treat. 2019. PMID: 30350268

119

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.

Seo Y, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY. Seo Y, et al. Among authors: park yh. J Breast Cancer. 2018 Dec;21(4):382-390. doi: 10.4048/jbc.2018.21.e48. Epub 2018 Oct 29. J Breast Cancer. 2018. PMID: 30607159 Free PMC article.

120

The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans.

Kim H, Choi DH, Park W, Im YH, Ahn JS, Park YH, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Jung BY. Kim H, et al. Among authors: park yh, park w. Hered Cancer Clin Pract. 2019 Jan 3;17:1. doi: 10.1186/s13053-018-0103-3. eCollection 2019. Hered Cancer Clin Pract. 2019. PMID: 30622657 Free PMC article.

121

Clinical features and prognosis of breast cancer with gastric metastasis.

Hong J, Kim Y, Cho J, Lim SW, Park SE, Kim HK, Lee H, Cho SY, Kim JY, Ahn JS, Im YH, Park YH. Hong J, et al. Among authors: park yh, park se. Oncol Lett. 2019 Feb;17(2):1833-1841. doi: 10.3892/ol.2018.9754. Epub 2018 Nov 23. Oncol Lett. 2019. PMID: 30675245 Free PMC article.

122

Insights Into Breast Cancer in the East vs the West: A Review.

Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. Yap YS, et al. Among authors: park yh. JAMA Oncol. 2019 Oct 1;5(10):1489-1496. doi: 10.1001/jamaoncol.2019.0620. JAMA Oncol. 2019. PMID: 31095268

123

Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry.

Kim JY, Kang D, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Im YH, Ahn JS, Guallar E, Cho J, Park YH. Kim JY, et al. Among authors: park yh. J Glob Oncol. 2019 Jul;5:1-9. doi: 10.1200/JGO.19.00034. J Glob Oncol. 2019. PMID: 31260394 Free PMC article.

124

Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT).

Kang D, Kim IR, Park YH, Im YH, Zhao D, Guallar E, Ahn JS, Cho J. Kang D, et al. Among authors: park yh. Support Care Cancer. 2020 Apr;28(4):1829-1837. doi: 10.1007/s00520-019-04982-z. Epub 2019 Jul 23. Support Care Cancer. 2020. PMID: 31338640 Clinical Trial.

125

Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12).

Kim JS, Kim K, Jung W, Shin KH, Im SA, Kim HJ, Kim YB, Chang JS, Choi DH, Park YH, Kim DY, Kim TH, Choi BO, Lee SW, Kim S, Kwon J, Kang KM, Chung WK, Kim KS, Nam JH, Yoon WS, Kim JH, Cha J, Oh YK, Kim IA. Kim JS, et al. Among authors: park yh. Breast. 2020 Feb;49:41-47. doi: 10.1016/j.breast.2019.10.007. Epub 2019 Oct 22. Breast. 2020. PMID: 31677532 Free PMC article.

126

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast.

Jang Y, Jung H, Kim HN, Seo Y, Alsharif E, Nam SJ, Kim SW, Lee JE, Park YH, Cho EY, Cho SY. Jang Y, et al. Among authors: park yh. J Pathol Transl Med. 2020 Jan;54(1):95-102. doi: 10.4132/jptm.2019.10.24. Epub 2019 Nov 13. J Pathol Transl Med. 2020. PMID: 31718120 Free PMC article.

127

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.

Hur JY, Kim JY, Ahn JS, Im YH, Lee J, Kwon M, Park YH. Hur JY, et al. Among authors: park yh. Cancers (Basel). 2020 May 21;12(5):1306. doi: 10.3390/cancers12051306. Cancers (Basel). 2020. PMID: 32455662 Free PMC article.

128

Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer.

Kim JY, Jung HH, Sohn I, Woo SY, Cho H, Cho EY, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Im YH. Kim JY, et al. Among authors: park yh. Breast Cancer Res Treat. 2020 Nov;184(2):325-334. doi: 10.1007/s10549-020-05874-1. Epub 2020 Aug 18. Breast Cancer Res Treat. 2020. PMID: 32812178

129

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.

Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Park WY. Hong TH, et al. Among authors: park yh, park s, park k, park wy. J Immunother Cancer. 2020 Oct;8(2):e001199. doi: 10.1136/jitc-2020-001199. J Immunother Cancer. 2020. PMID: 33077514 Free PMC article.

130

Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.

Kim HK, Lee HS, Heo MH, Kim JY, Ahn JS, Im YH, Lee JI, Park YH. Kim HK, et al. Among authors: park yh. Clin Breast Cancer. 2021 Aug;21(4):e402-e414. doi: 10.1016/j.clbc.2020.12.013. Epub 2021 Jan 6. Clin Breast Cancer. 2021. PMID: 33526378 Free article.

131

Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea.

Hong J, Lee J, Kwon M, Kim JY, Kim JW, Ahn JS, Im YH, Park YH. Hong J, et al. Among authors: park yh. Diagnostics (Basel). 2021 Feb 22;11(2):370. doi: 10.3390/diagnostics11020370. Diagnostics (Basel). 2021. PMID: 33671539 Free PMC article.

132

The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study.

Lee K, Sim SH, Kang EJ, Seo JH, Chae H, Lee KS, Kim JY, Ahn JS, Im YH, Park S, Park YH, Park IH. Lee K, et al. Among authors: park yh, park ih, park s. Front Oncol. 2021 Mar 5;11:653243. doi: 10.3389/fonc.2021.653243. eCollection 2021. Front Oncol. 2021. PMID: 33747970 Free PMC article.

133

Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry.

Kim JY, Lee YS, Yu J, Park Y, Lee SK, Lee M, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Kang M, Im YH. Kim JY, et al. Among authors: park yh, park y. Front Oncol. 2021 May 4;11:596364. doi: 10.3389/fonc.2021.596364. eCollection 2021. Front Oncol. 2021. PMID: 34017679 Free PMC article.

134

Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.

Kim JY, Jeon E, Kwon S, Jung H, Joo S, Park Y, Lee SK, Lee JE, Nam SJ, Cho EY, Park YH, Ahn JS, Im YH. Kim JY, et al. Among authors: park yh, park y. Breast Cancer Res Treat. 2021 Oct;189(3):747-757. doi: 10.1007/s10549-021-06310-8. Epub 2021 Jul 5. Breast Cancer Res Treat. 2021. PMID: 34224056

135

Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial.

Kang D, Kim N, Im YH, Park YH, Kim JY, Park H, Kim E, Zhao D, Guallar E, Ahn JS, Cho J. Kang D, et al. Among authors: park yh, park h. J Am Acad Dermatol. 2022 Oct;87(4):858-860. doi: 10.1016/j.jaad.2021.10.047. Epub 2021 Oct 30. J Am Acad Dermatol. 2022. PMID: 34728262 Clinical Trial. No abstract available.

136

Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?

Kim JY, Oh JM, Park YH, Ahn JS, Im YH. Kim JY, et al. Among authors: park yh. Front Oncol. 2021 Oct 21;11:759150. doi: 10.3389/fonc.2021.759150. eCollection 2021. Front Oncol. 2021. PMID: 34745997 Free PMC article.

137

Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Jung HH, Kim JY, Cho EY, Oh JM, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Im YH. Jung HH, et al. Among authors: park yh. Cancers (Basel). 2021 Oct 20;13(21):5260. doi: 10.3390/cancers13215260. Cancers (Basel). 2021. PMID: 34771423 Free PMC article.

138

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.

Kim H, Kim HJ, Kim H, Kim HR, Jo H, Hong J, Kim R, Kim JY, Ahn JS, Im YH, Lee SK, Kim H, Shin SY, Park YH. Kim H, et al. Among authors: park yh. Cancers (Basel). 2021 Nov 21;13(22):5835. doi: 10.3390/cancers13225835. Cancers (Basel). 2021. PMID: 34830990 Free PMC article.

139

The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12).

Kim JS, Kim K, Jung W, Shin KH, Im SA, Kim HJ, Kim YB, Chang JS, Kim JH, Choi DH, Park YH, Kim DY, Kim TH, Choi BO, Lee SW, Kim S, Kwon J, Kang KM, Chung WK, Kim KS, Nam JH, Yoon WS, Kim JH, Cha J, Oh YK, Kim IA. Kim JS, et al. Among authors: park yh. Cancer Res Treat. 2022 Oct;54(4):1121-1129. doi: 10.4143/crt.2021.1083. Epub 2021 Dec 31. Cancer Res Treat. 2022. PMID: 34990524 Free PMC article.

140

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.

Kim JY, Nam SJ, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM, Ahn JS, Im YH, Kim SW, Park YH. Kim JY, et al. Among authors: park yh. Cancer Res Treat. 2022 Oct;54(4):1091-1098. doi: 10.4143/crt.2021.901. Epub 2022 Jan 10. Cancer Res Treat. 2022. PMID: 35008143 Free PMC article.

141

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.

Lee YP, Lee MS, Kim H, Kim JY, Ahn JS, Im YH, Park YH. Lee YP, et al. Among authors: park yh. Cancer Res Treat. 2022 Oct;54(4):1130-1137. doi: 10.4143/crt.2021.1103. Epub 2022 Jan 17. Cancer Res Treat. 2022. PMID: 35038825 Free PMC article. Clinical Trial.

142

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.

Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. Tan RSYC, et al. Among authors: park yh, park s. BMC Med. 2022 Mar 17;20(1):105. doi: 10.1186/s12916-022-02284-6. BMC Med. 2022. PMID: 35296300 Free PMC article.

143

Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study.

Kang D, Kang M, Hong YS, Park J, Lee J, Seo HJ, Kim DW, Ahn JS, Park YH, Lee SK, Shin DW, Guallar E, Cho J. Kang D, et al. Among authors: park yh, park j. Sci Rep. 2022 Mar 31;12(1):5489. doi: 10.1038/s41598-022-09542-w. Sci Rep. 2022. PMID: 35361864 Free PMC article.

144

Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.

Kwon WK, Jang HJ, Lee JE, Park YH, Ryu JM, Yu J, Jang JH, Kim JW. Kwon WK, et al. Among authors: park yh. Cancer Genet. 2022 Aug;266-267:19-27. doi: 10.1016/j.cancergen.2022.05.042. Epub 2022 May 28. Cancer Genet. 2022. PMID: 35671604 Review.

145

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.

Kim JY, Oh JM, Lee SK, Yu J, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Kim K, Im YH. Kim JY, et al. Among authors: park yh. Front Oncol. 2022 Jun 7;12:903372. doi: 10.3389/fonc.2022.903372. eCollection 2022. Front Oncol. 2022. PMID: 35747813 Free PMC article.

146

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03).

Lee DW, Keam B, Lee KS, Ahn JH, Sohn J, Ahn JS, Lee MH, Kim JH, Lee KE, Kim HJ, Kim SY, Park YH, Ock CY, Lee KH, Han SW, Kim SB, Im YH, Chung HC, Oh DY, Im SA. Lee DW, et al. Among authors: park yh. Cancer Res Treat. 2023 Apr;55(2):523-530. doi: 10.4143/crt.2022.1360. Epub 2022 Nov 8. Cancer Res Treat. 2023. PMID: 36397238 Free PMC article. Clinical Trial.

147

COPD Exacerbation-Related Pathogens and Previous COPD Treatment.

Sim YS, Lee JH, Lee EG, Choi JY, Lee CH, An TJ, Park Y, Yoon YS, Park JH, Yoo KH. Sim YS, et al. J Clin Med. 2022 Dec 23;12(1):111. doi: 10.3390/jcm12010111. J Clin Med. 2022. PMID: 36614912 Free PMC article.

148

Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).

Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, Sim SH, Ueno T, Futamura M, Toi M, Fujiwara Y, Ahn SG, Lee JE, Park YH, Takao S, Oba MS, Kitagawa Y, Nishiyama M. Imoto S, et al. Among authors: park yh. Breast Cancer. 2023 May;30(3):412-423. doi: 10.1007/s12282-023-01436-7. Epub 2023 Jan 23. Breast Cancer. 2023. PMID: 36689066

149

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer.

Kim JY, Kim J, Cho EY, Park YH, Ahn JS, Kim KM, Im YH. Kim JY, et al. Among authors: park yh. Front Oncol. 2023 Mar 16;13:1146934. doi: 10.3389/fonc.2023.1146934. eCollection 2023. Front Oncol. 2023. PMID: 37007114 Free PMC article.

150

Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer.

Lee H, Choi JY, Park YH, Lee JE, Kim SW, Nam SJ, Cho YS. Lee H, et al. Among authors: park yh. Cancers (Basel). 2023 May 7;15(9):2646. doi: 10.3390/cancers15092646. Cancers (Basel). 2023. PMID: 37174111 Free PMC article.

151

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer.

Kim JY, Park S, Cho EY, Lee JE, Jung HH, Chae BJ, Kim SW, Nam SJ, Cho SY, Park YH, Ahn JS, Lee S, Im YH. Kim JY, et al. Among authors: park yh, park s. Exp Mol Med. 2023 Jul;55(7):1451-1461. doi: 10.1038/s12276-023-01030-z. Epub 2023 Jul 3. Exp Mol Med. 2023. PMID: 37394589 Free PMC article.

152

Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study.

Kwak Y, Jang SY, Choi JY, Lee H, Shin DS, Park YH, Kim JY, Ahn JS, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. Kwak Y, et al. Among authors: park yh. Cancers (Basel). 2023 Jun 30;15(13):3435. doi: 10.3390/cancers15133435. Cancers (Basel). 2023. PMID: 37444546 Free PMC article.

153

Pretreatment endocrine symptoms and recurrence-free survival among young premenopausal patients with breast cancer: a prospective cohort study.

Kang D, Cho J, Park S, Kim HJ, Kim SW, Lee JE, Yu J, Lee SK, Kim JY, Nam SJ, Park YH. Kang D, et al. Among authors: park yh, park s. Ther Adv Med Oncol. 2023 Aug 1;15:17588359231189421. doi: 10.1177/17588359231189421. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37547446 Free PMC article.

154

Impact of Social Support during Diagnosis and Treatment on Disease Progression in Young Patients with Breast Cancer: A Prospective Cohort Study.

Kang D, Park S, Kim HJ, Kim SW, Lee JE, Yu J, Lee SK, Kim JY, Nam SJ, Cho J, Park YH. Kang D, et al. Among authors: park yh, park s. Cancer Res Treat. 2024 Jan;56(1):125-133. doi: 10.4143/crt.2023.673. Epub 2023 Sep 4. Cancer Res Treat. 2024. PMID: 37669709 Free PMC article.

155

Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach.

Kim N, Kim H, Park W, Cho WK, Kim TG, Im YH, Ahn JS, Park YH, Kim JY. Kim N, et al. Among authors: park yh, park w. Radiat Oncol. 2023 Oct 11;18(1):168. doi: 10.1186/s13014-023-02357-7. Radiat Oncol. 2023. PMID: 37821947 Free PMC article. Review.

156

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.

Kim N, Kim JY, Park W, Cho WK, Kim TG, Im YH, Ahn JS, Lee JE, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Park YH, Kim H. Kim N, et al. Among authors: park yh, park w. Breast. 2023 Dec;72:103594. doi: 10.1016/j.breast.2023.103594. Epub 2023 Oct 30. Breast. 2023. PMID: 37924622 Free PMC article.

157

A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).

Baek SK, Jeong JH, Jung K, Ahn HK, Kim MH, Sohn J, Park IH, Ahn JS, Lee DW, Im SA, Sim SH, Lee KS, Hyun Kim J, Shim HJ, Chae Y, Koh SJ, Lee H, Lee J, Byun JH, Seol Y, Lee EM, Jee HJ, An H, Park EB, Suh YJ, Lee KE, Park YH; Korean Cancer Study Group (KCSG). Baek SK, et al. Among authors: park ih, park yh, park eb. Ther Adv Med Oncol. 2024 Jan 28;16:17588359231225029. doi: 10.1177/17588359231225029. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38288157 Free PMC article.

158

Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile.

Kang D, Park S, Kim HJ, Lee J, Han J, Kim SW, Lee JE, Yu J, Lee SK, Kim JY, Nam SJ, Cho J, Park YH. Kang D, et al. Among authors: park yh, park s. Breast Cancer. 2024 May;31(3):467-475. doi: 10.1007/s12282-024-01559-5. Epub 2024 Mar 12. Breast Cancer. 2024. PMID: 38472736

159

Primary malignant lymphoma of the breast: clinicopathological study of nine cases.

Park YH, Kim SH, Choi SJ, Ryoo BY, Kang YK, Lee SS. Park YH, et al. Leuk Lymphoma. 2004 Feb;45(2):327-30. doi: 10.1080/10428190310001597892. Leuk Lymphoma. 2004. PMID: 15101719

160

Secondary hematological malignancies after breast cancer chemotherapy.

Park MJ, Park YH, Ahn HJ, Choi W, Paik KH, Kim JM, Chang YH, Ryoo BY, Yang SH. Park MJ, et al. Among authors: park yh. Leuk Lymphoma. 2005 Aug;46(8):1183-8. doi: 10.1080/10428190500125705. Leuk Lymphoma. 2005. PMID: 16085560

161

Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.

Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK. Kim TM, et al. Among authors: park yh. Blood. 2005 Dec 1;106(12):3785-90. doi: 10.1182/blood-2005-05-2056. Epub 2005 Aug 18. Blood. 2005. PMID: 16109779 Free article.

162

What is the best treatment for primary breast lymphoma? Combined modality should be adapted according to the risk stratification.

Park YH. Park YH. Leuk Lymphoma. 2006 Oct;47(10):2011-2. doi: 10.1080/10428190600733341. Leuk Lymphoma. 2006. PMID: 17071469 No abstract available.

163

Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.

Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH. Lee JJ, et al. Among authors: park yh. Br J Haematol. 2007 May;137(4):329-36. doi: 10.1111/j.1365-2141.2007.06570.x. Epub 2007 Apr 4. Br J Haematol. 2007. PMID: 17408400 Free article.

164

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.

Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Kim JG, et al. Among authors: park yh. Cancer Chemother Pharmacol. 2008 Feb;61(2):301-7. doi: 10.1007/s00280-007-0476-x. Epub 2007 Apr 12. Cancer Chemother Pharmacol. 2008. PMID: 17429626

165

Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.

Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ. Kim HS, et al. Among authors: park yh, park k. Cancer. 2010 Feb 1;116(3):676-85. doi: 10.1002/cncr.24748. Cancer. 2010. PMID: 20052735 Free article.

166

Dermatomyositis and Paclitaxel-Induced Cutaneous Drug Eruption Associated with Metastatic Breast Cancer.

Kim Y, Jung W, Park YH. Kim Y, et al. Among authors: park yh. J Breast Cancer. 2015 Jun;18(2):195-9. doi: 10.4048/jbc.2015.18.2.195. Epub 2015 Jun 26. J Breast Cancer. 2015. PMID: 26155297 Free PMC article.

167

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.

Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH. Park YH, et al. Among authors: park ih. Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3. Cancer Res Treat. 2017. PMID: 27488876 Free PMC article. Clinical Trial.

168

Isolated pachymeningeal metastasis from breast cancer: Clinical features and prognostic factors.

Heo MH, Cho YJ, Kim HK, Kim JY, Park YH. Heo MH, et al. Among authors: park yh. Breast. 2017 Oct;35:109-114. doi: 10.1016/j.breast.2017.07.006. Epub 2017 Jul 11. Breast. 2017. PMID: 28709114

169

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.

Heo MH, Kim HK, Lee H, Kim JY, Ahn JS, Im YH, Park YH. Heo MH, et al. Among authors: park yh. Korean J Intern Med. 2019 Sep;34(5):1100-1106. doi: 10.3904/kjim.2017.226. Epub 2018 Mar 16. Korean J Intern Med. 2019. PMID: 29540055 Free PMC article.

170

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.

Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y. Fujiwara Y, et al. Among authors: park yh. Br J Cancer. 2019 Mar;120(5):475-480. doi: 10.1038/s41416-019-0391-z. Epub 2019 Feb 12. Br J Cancer. 2019. PMID: 30745582 Free PMC article. Clinical Trial.

171

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).

Kim JY, Park S, Im SA, Kim SB, Sohn J, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH, Park YH; Korean Cancer Study Group. Kim JY, et al. Among authors: park ih, park yh, park s. Cancer Commun (Lond). 2019 May 28;39(1):29. doi: 10.1186/s40880-019-0375-7. Cancer Commun (Lond). 2019. PMID: 31138332 Free PMC article. Clinical Trial.

172

Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.

Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS; Asian Breast Cancer Cooperative Group. Yeo W, et al. Among authors: park yh. Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4. Breast Cancer Res Treat. 2019. PMID: 31270763 Review.

173

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).

Sim SH, Park IH, Jung KH, Kim SB, Ahn JH, Lee KH, Im SA, Im YH, Park YH, Sohn J, Kim YJ, Lee S, Kim HJ, Chae YS, Park KH, Nam BH, Lee KS, Ro J. Sim SH, et al. Among authors: park ih, park yh, park kh. Br J Cancer. 2019 Dec;121(12):985-990. doi: 10.1038/s41416-019-0618-z. Epub 2019 Nov 6. Br J Cancer. 2019. PMID: 31690831 Free PMC article. Clinical Trial.

174

Immune gene expression profiling reveals heterogeneity in luminal breast tumors.

Zhu B, Tse LA, Wang D, Koka H, Zhang T, Abubakar M, Lee P, Wang F, Wu C, Tsang KH, Chan WC, Law SH, Li M, Li W, Wu S, Liu Z, Huang B, Zhang H, Tang E, Kan Z, Lee S, Park YH, Nam SJ, Wang M, Sun X, Jones K, Zhu B, Hutchinson A, Hicks B, Prokunina-Olsson L, Shi J, Garcia-Closas M, Chanock S, Yang XR. Zhu B, et al. Among authors: park yh. Breast Cancer Res. 2019 Dec 19;21(1):147. doi: 10.1186/s13058-019-1218-9. Breast Cancer Res. 2019. PMID: 31856876 Free PMC article.

175

A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.

Lu YS, Lee KS, Chao TY, Tseng LM, Chitapanarux I, Chen SC, Liu CT, Sohn J, Kim JH, Chang YC, Yang Y, Shotelersuk K, Jung KH, Valenti R, Slader C, Gao M, Park YH. Lu YS, et al. Among authors: park yh. Clin Cancer Res. 2021 Jan 15;27(2):408-417. doi: 10.1158/1078-0432.CCR-20-1008. Epub 2020 Jul 27. Clin Cancer Res. 2021. PMID: 32718997

176

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).

Lee J, Im SA, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park YH. Lee J, et al. Among authors: park ih, park yh. Cancer Res Treat. 2021 Jul;53(3):695-702. doi: 10.4143/crt.2020.1246. Epub 2020 Dec 17. Cancer Res Treat. 2021. PMID: 33332933 Free PMC article.

177

New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).

Kim JS, Kim K, Jung W, Shin KH, Im SA, Kim HJ, Kim YB, Chang JS, Kim JH, Choi DH, Park YH, Kim DY, Kim TH, Choi BO, Lee SW, Kim S, Kwon J, Kang KM, Chung WK, Kim KS, Yoon WS, Kim JH, Cha J, Oh YK, Kim IA. Kim JS, et al. Among authors: park yh. Breast Cancer Res Treat. 2021 Apr;186(2):453-462. doi: 10.1007/s10549-020-06043-0. Epub 2021 Jan 4. Breast Cancer Res Treat. 2021. PMID: 33392845

178

An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer.

Lu YS, Yeo W, Yap YS, Park YH, Tamura K, Li H, Cheng R. Lu YS, et al. Among authors: park yh. Target Oncol. 2021 Nov;16(6):701-741. doi: 10.1007/s11523-021-00838-x. Epub 2021 Sep 28. Target Oncol. 2021. PMID: 34582007 Free PMC article. Review.

179

Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).

Kim SH, Im SA, Suh KJ, Lee KH, Kim MH, Sohn J, Park YH, Kim JY, Jeong JH, Lee KE, Choi IS, Park KH, Kim HJ, Cho EK, Park SY, Kim M, Kim JH. Kim SH, et al. Among authors: park yh, park kh, park sy. Eur J Cancer. 2023 Dec;195:113386. doi: 10.1016/j.ejca.2023.113386. Epub 2023 Oct 14. Eur J Cancer. 2023. PMID: 37890351 Free article. Clinical Trial.

180

Peripheral T-cell lymphoma-unspecified (PTCL-U) presenting with hypereosinophilic syndrome and pleural effusions.

Choi W, Park YH, Paik KH, Chang YH, Lee SS, Ryoo BY, Yang SH. Choi W, et al. Among authors: park yh. Korean J Intern Med. 2006 Mar;21(1):57-61. doi: 10.3904/kjim.2006.21.1.57. Korean J Intern Med. 2006. PMID: 16646567 Free PMC article.

181

Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.

Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH. Park YH, et al. Clin Cancer Res. 2009 Mar 15;15(6):2107-15. doi: 10.1158/1078-0432.CCR-08-1588. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276283

182

Meeting highlights: the first korean breast cancer treatment consensus conference.

Han A, Lee KE, Lee HK, Park YH, Kim J, Kim SW, Jung KH, Son BH; Korean Breast Cancer Treatment Consensus Conference Panelists. Han A, et al. Among authors: park yh. J Breast Cancer. 2014 Dec;17(4):308-13. doi: 10.4048/jbc.2014.17.4.308. Epub 2014 Dec 26. J Breast Cancer. 2014. PMID: 25548577 Free PMC article. Review.

183

Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: park ih. Eur J Cancer. 2017 Nov;86:385-393. doi: 10.1016/j.ejca.2017.10.002. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29100193 Clinical Trial.

184

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).

Park IH, Im SA, Jung KH, Sohn JH, Park YH, Lee KS, Sim SH, Park KH, Kim JH, Nam BH, Kim HJ, Kim TY, Lee KH, Kim SB, Ahn JH, Lee S, Ro J. Park IH, et al. Among authors: park yh, park kh. Cancer Res Treat. 2019 Jan;51(1):43-52. doi: 10.4143/crt.2017.562. Epub 2018 Feb 14. Cancer Res Treat. 2019. PMID: 29458237 Free PMC article. Clinical Trial.

185

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.

Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Kim JY, Lee KH, Sohn J, Kim SB, Ahn JS, Im YH, Jung KH, Im SA; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: park ih. Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24. Lancet Oncol. 2019. PMID: 31668850 Clinical Trial.

186

Pembrolizumab for Early Triple-Negative Breast Cancer.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: park yh. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.

187

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Rugo HS, et al. Among authors: park yh. Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6. Lancet Oncol. 2021. PMID: 33794206 Clinical Trial.

188

Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12).

Kim JS, Kim K, Jung W, Shin KH, Im SA, Kim YB, Chang JS, Choi DH, Kim H, Park YH, Kim DY, Kim TH, Kwon J, Kang KM, Chung WK, Kim KS, Kim IA. Kim JS, et al. Among authors: park yh. Breast. 2021 Dec;60:272-278. doi: 10.1016/j.breast.2021.11.005. Epub 2021 Nov 15. Breast. 2021. PMID: 34814043 Free PMC article.

189

Trastuzumab deruxtecan for HER2+ advanced breast cancer.

Lee J, Park YH. Lee J, et al. Among authors: park yh. Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26. Future Oncol. 2022. PMID: 34823373 Review.

190

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Lee S, Park K, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park WY, Im SA, Park YH. Lee S, et al. Among authors: park ih, park yh, park k, park wy. Breast. 2022 Apr;62:52-60. doi: 10.1016/j.breast.2022.01.014. Epub 2022 Jan 29. Breast. 2022. PMID: 35124320 Free PMC article. Clinical Trial.

191

The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology.

Hirko KA, Rocque G, Reasor E, Taye A, Daly A, Cutress RI, Copson ER, Lee DW, Lee KH, Im SA, Park YH. Hirko KA, et al. Among authors: park yh. BMC Med. 2022 Feb 11;20(1):72. doi: 10.1186/s12916-022-02260-0. BMC Med. 2022. PMID: 35151316 Free PMC article.

192

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.

Hong J, Park YH. Hong J, et al. Among authors: park yh. Ther Adv Med Oncol. 2022 Jun 21;14:17588359221106564. doi: 10.1177/17588359221106564. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35756967 Free PMC article. Review.

193

Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.

Ahn HK, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, Lee DW, Ahn JH, Chae H, Lee KH, Kim JH, Lee KS, Sohn JH, Choi YL, Im SA, Jung KH, Park YH. Ahn HK, et al. Among authors: park yh. JAMA Oncol. 2022 Sep 1;8(9):1271-1277. doi: 10.1001/jamaoncol.2022.2310. JAMA Oncol. 2022. PMID: 35797012 Free PMC article. Clinical Trial.

194

A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer.

Lee HB, Lee KH, Song SH, Kim K, Kim HK, Moon HG, Han W, Lee DW, Im SA, Jang BS, Kim YB, Yu J, Kim JH, Park YH, Shin KH, Chang JH. Lee HB, et al. Among authors: park yh. Oncologist. 2023 Dec 11;28(12):e1142-e1151. doi: 10.1093/oncolo/oyad156. Oncologist. 2023. PMID: 37279777 Free PMC article.

195

Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial.

Lee DW, Jung KH, Lee KH, Park YH, Lee KS, Sohn J, Ahn HK, Jeong JH, Koh SJ, Kim JH, Kim HJ, Lee KE, Kim HJ, Yang YW, Park KH, Lee J, Won HS, Kim TY, Im SA. Lee DW, et al. Among authors: park yh, park kh. Eur J Cancer. 2024 Jan;197:113456. doi: 10.1016/j.ejca.2023.113456. Epub 2023 Nov 20. Eur J Cancer. 2024. PMID: 38104354 Clinical Trial.

196

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK. Park YH, et al. Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9. doi: 10.1007/s00280-007-0515-7. Epub 2007 May 24. Cancer Chemother Pharmacol. 2008. PMID: 17522863 Clinical Trial.

197

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA).

Choi MK, Park YH, Hong JY, Park HC, Ahn YC, Kim K, Shim YM, Kang WK, Park K, Im YH. Choi MK, et al. Among authors: park yh, park hc, park k. Med Oncol. 2010 Dec;27(4):1234-8. doi: 10.1007/s12032-009-9364-z. Epub 2009 Nov 19. Med Oncol. 2010. PMID: 19924573

198

Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck.

Sun JM, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ. Sun JM, et al. Among authors: park yh, park k. Oral Oncol. 2011 Aug;47(8):714-9. doi: 10.1016/j.oraloncology.2011.06.007. Epub 2011 Jun 25. Oral Oncol. 2011. PMID: 21708479

199

A case report of paraneoplastic pemphigus associated with esophageal squamous cell carcinoma.

Cho JH, Kim NJ, Ko SM, Kim C, Ahn HK, Yun J, Park YH. Cho JH, et al. Among authors: park yh. Cancer Res Treat. 2013 Mar;45(1):70-3. doi: 10.4143/crt.2013.45.1.70. Epub 2013 Mar 31. Cancer Res Treat. 2013. PMID: 23613673 Free PMC article.

200

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.

Lee SJ, Kim S, Kim M, Lee J, Park YH, Im YH, Park SH. Lee SJ, et al. Among authors: park yh, park sh. BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9. BMC Cancer. 2015. PMID: 26468007 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,003 results

Search Page